Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
16.09. | ArcStone US Corp.: Lobe Sciences Ltd. to Attend the ArcStone-Kingswood Growth Summit 2025 in Toronto | 489 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - September 15, 2025) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (FSE: LOBE.F) ("Lobe Sciences" or the "Company") a clinical stage biopharmaceutical... ► Artikel lesen | |
10.09. | Lobe Sciences Ltd. and Cynaptec Pharmaceuticals, Inc. to Present a New Therapeutic Approach for the Treatment of Chronic Cluster Headaches at Clusterbusters 2025 | 351 | ACCESS Newswire | VANCOUVER, B.C. / ACCESS Newswire / September 9, 2025 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) a clinical stage biopharmaceutical company focused on developing... ► Artikel lesen | |
09.09. | Lobe Sciences Ltd.: Lobe Sciences Announces the Appointment of Marco Mastrodonato to its Board of Directors | 330 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / September 8, 2025 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) a clinical stage biopharmaceutical company focused on... ► Artikel lesen | |
15.08. | Lobe Sciences Ltd.: Lobe Sciences Announces the Closing of the Previously Announced Private Placement | 378 | ACCESS Newswire | NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESS Newswire / August 14, 2025 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company")... ► Artikel lesen | |
29.07. | Lobe Sciences Ltd (2): Lobe Sciences arranges private placement | 2 | Stockwatch | ||
LOBE SCIENCES Aktie jetzt für 0€ handeln | |||||
29.07. | Lobe Sciences Ltd (2): Lobe Sciences hires ArcStone for advisory services | 1 | Stockwatch | ||
29.07. | Lobe Sciences Ltd. Engages ArcStone Securities for Strategic Capital Markets Advisory | 400 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / July 29, 2025 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a biopharmaceutical company focused on developing therapeutics for rare and underserved diseases... ► Artikel lesen | |
29.07. | Lobe Sciences Ltd.: Lobe Sciences Announces $341,425 CAD Private Placement for General Corporate Purposes | 427 | ACCESS Newswire | NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / July 29, 2025 / Lobe Sciences Ltd. ("Lobe Sciences"... ► Artikel lesen | |
17.07. | Lobe Sciences Ltd (2): Lobe Sciences issues 546,206 shares for debt of $11,596 | 2 | Stockwatch | ||
17.07. | Lobe Sciences announces debt settlement | - | Seeking Alpha | ||
17.07. | Lobe Sciences Ltd. Announces Debt Settlement | 361 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / July 16, 2025 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a biopharmaceutical company committed to developing innovative treatments for underserved diseases... ► Artikel lesen | |
08.07. | Lobe Sciences Ltd (2): Lobe Sciences receives European unitary patent | 1 | Stockwatch | ||
08.07. | Lobe Sciences Ltd.: Lobe Sciences Announces Validation of European Unitary Patent for DHA-Based Composition for Sickle Cell Disease | 657 | ACCESS Newswire | European Unitary Patent EP4117446 Validated - Lobe Sciences secures patent protection in 17 EU member states for its DHA and egg yolk-based composition designed to manage Sickle Cell Disease.Covers... ► Artikel lesen | |
18.06. | Lobe Sciences Ltd.: Lobe Sciences Moves Forward with Development of Conjugated Psilocin Following April 14 Agreement to Spin Out Compound to Cynaptec Pharmaceuticals | 306 | ACCESS Newswire | New subsidiary, Cynaptec Pharmaceuticals, established to hold global rights to Conjugated Psilocin$6 million investment in Cynaptec Pharmaceuticals secured to advance research and early-stage clinical... ► Artikel lesen | |
03.06. | Lobe Sciences Ltd (2): Lobe Sciences appoints Yao as CFO, EVP | 3 | Stockwatch | ||
03.06. | Lobe Sciences Ltd.: Lobe Sciences Appoints Mr. Yong Yao as Chief Financial Officer to Support Strategic Growth | 320 | ACCESS Newswire | Lobe Sciences Ltd. has appointed Mr. Yong Yao as Chief Financial Officer and Executive Vice President, effective June 1, 2025, to lead the company's financial strategy during its next phase of growth.Mr.... ► Artikel lesen | |
14.04. | Lobe Sciences Ltd (2): Lobe's Cynaptec arranges $6M (U.S.) private placement | 1 | Stockwatch | ||
14.04. | Lobe Sciences Ltd. Announces Private Placement to Support Drug Development of Novel Conjugated Psilocin | 219 | ACCESS Newswire | Private Placement of US$6 Million to fund additional pre-clinical research, Phase 1 and Phase 2a clinical studiesUS$20 Million additional option included in Private Placement to fund the Phase 3 clinical... ► Artikel lesen | |
05.04. | Lobe Sciences Ltd.: Lobe Sciences Provides Corporate Update | 717 | ACCESS Newswire | VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / April 4, 2025 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a commercial stage biopharmaceutical company focused... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
CORE ONE LABS | 0,079 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.09.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 22.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.09.2025ISIN NameAU000000PEK2 PEAK... ► Artikel lesen | |
BIONXT SOLUTIONS | 0,518 | +0,39 % | Übernahme im Ozempic-Markt! Jetzt BioNxt Solutions? Novo Nordisk, Elli Lilly und Pfizer kämpfen! | Der Kampf gegen Fettleibigkeit gilt als einer der größten Wachstumsmärkte im globalen Pharmasektor. Schätzungen zufolge könnte der Markt für Adipositas-Therapien bis 2030 ein Volumen von bis zu 150... ► Artikel lesen | |
AMYRIS | - | - | Amyris gains sole control of Brazilian fermentation facility | ||
ATAI LIFE SCIENCES | 4,440 | +2,45 % | Atai Life Sciences files to sell 45.32M common shares by selling shareholders | ||
SOL GLOBAL INVESTMENTS | 0,030 | -6,54 % | SOL Global Investments Corp.: SOL Global CEO Davide Marcotti Charts Strategic Growth Path with International Investor Outreach | Toronto, Ontario--(Newsfile Corp. - September 22, 2025) - SOL Global Investments Corp. (CSE: SOL) (OTCID: SOLCF) (FSE: 9SB) ("SOL Global" or the "Company") is pleased to provide an update under the... ► Artikel lesen | |
REVIVE THERAPEUTICS | 0,001 | -80,00 % | Revive Therapeutics Ltd.: Revive Therapeutics Announces Closing of First Tranche of Private Placement and Debt Settlement | TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing... ► Artikel lesen | |
CYBIN | 5,250 | -0,94 % | Cybin gibt Update zur Neuropsychiatrie-Plattform und bevorstehenden klinischen Meilensteinen | - Erfolgreich abgeschlossene Aufnahme von 36 Teilnehmern in die Phase-2-Studie zu CYB004, dem DMT-Programm (deuteriertes Dimethyltryptamin, "DMT") des Unternehmens zur
Behandlung der... ► Artikel lesen | |
RAPID DOSE THERAPEUTICS | - | - | Rapid Dose Therapeutics Corp.: Rapid Dose Announces Payment in Shares for Quarterly Interest on Secured Debt | Burlington, Ontario--(Newsfile Corp. - October 2, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") announced today that as contemplated in the secured convertible notes (the... ► Artikel lesen | |
ADMA BIOLOGICS | 14,660 | +0,89 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
QIAGEN | 39,740 | +0,68 % | Kaum Impulse für die Qiagen NV-Aktie (37,58 €) | Wenig Kursbewegung zur Stunde bei dem Anteilsschein von Qiagen NV . Der jüngste Kurs betrug 37,58 Euro. Einen minimalen Wertanstieg von 0,17 Prozent zeigt die Kurstafel für der Anteilsschein von Qiagen... ► Artikel lesen | |
CG ONCOLOGY | 39,820 | -0,09 % | CG Oncology Inc.: CG Oncology Completes Enrollment in PIVOT-006 | - Rapid enrollment underscores high unmet need in intermediate-risk non-muscle invasive bladder cancer (NMIBC) -- One of the largest randomized phase 3 studies in this patient population will encompass... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,480 | -0,72 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update | SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and... ► Artikel lesen | |
ARVINAS | 9,610 | +3,61 % | Arvinas Inc.: Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders | ||
IMMUNOME | 12,380 | +7,93 % | Where Immunome Stands With Analysts |